Showing results (291-300 of 369) with videos related to

Sort By:
Pageof 37
Cancers|March 10, 2022
Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma PatientsBrett A Schroeder, Yuzheng Zhang, Kimberly S Smythe, et al.
Anticancer Research|March 27, 2026
Analysis of Clinical Benefit Using DNG64-CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing CancersSant P Chawla, Samantha Jeffrey, Skyler S Pang, et al.
Cancer Medicine|April 29, 2023
Physical symptom burden in patients with desmoid-type fibromatosis and its impact on health-related quality of life and healthcare useAnne-Rose W Schut, Leanne E de Bruin, Belle H de Rooij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue SarcomasValeriya Pankova, Lukas Krasny, William Kerrison, et al.
Oral Diseases|March 16, 2026
Genomic Landscape of Myoepithelial Carcinoma TumorsMayukha Kashyap, Hollis Wright, JiHyeon Byun, et al.
Future Oncology (London, England)|February 11, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcomaGregory M Cote, Sant P Chawla, George Demetri, et al.
Annals of Surgery|December 19, 2019
Oncological Outcome After Diagnostic Biopsies in Gastrointestinal Stromal Tumors: A Retrospective Cohort StudyWinan J van Houdt, Nikki S IJzerman, Anne Marjolein Schrijver, et al.
Cancer|April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomasRobin L Jones, Sant P Chawla, Steven Attia, et al.
Academic Radiology|November 26, 2024
Robotic MRI/CT Guided Multiregional 'smart' Biopsy for Characterization of Tumor Heterogeneity: A Prospective Development StudyEdward W Johnston, Jessica M Winfield, Amani Arthur, et al.
Nature Communications|March 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyMrinal Gounder, Patrick Schöffski, Robin L Jones, et al.
Pageof 37